Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
May 19, 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Cytovia Therapeutics Expands Leadership Team
May 13, 2021 09:48 ET
|
Cytovia Therapeutics
Jason Aryeh elected to Board of DirectorsElizabeth Schwarzbach, PhD and Boris Reznik, PhD join Strategic Advisory BoardElysa Mantel appointed as Vice President, General Counsel and Corporate Secretary...
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
April 28, 2021 13:16 ET
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
April 12, 2021 11:11 ET
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022
March 17, 2021 09:39 ET
|
Cytovia Therapeutics
R&D labs for NK cell biology, gene-editing, antibody and CAR development, and NK cell pilot manufacturing opens in Natick, MACell therapy manufacturing facility with best-in-industry clinical and...
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
March 08, 2021 10:24 ET
|
Cytovia Therapeutics
CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric...
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
January 13, 2021 07:47 ET
|
Cytovia Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company focusing on Natural Killer cells in cancer, announced today that it has signed a...
Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors
December 08, 2020 09:04 ET
|
Cytovia Therapeutics
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging NK cell therapeutics company, announced today that it plans to file with the FDA in 2021 an Investigational New...
Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference
November 12, 2020 07:30 ET
|
Cytovia Therapeutics
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in the...
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
October 08, 2020 06:00 ET
|
Cytovia Therapeutics
NEW YORK and PARIS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement...